Osteopore achieves medical product access in Saudi Arabia
- Regenerative medicine manufacturer Osteopore has secured market access to Saudi Arabia for its specialised craniofacial products.
- The company's shares remained steady at $0.005 following the announcement of the Middle Eastern expansion.
- The regulatory milestone expands the commercial reach of the company's 3D-printed biomimetic implants via an established global distribution network.
Regenerative medicine manufacturer Osteopore (ASX:OSX) has secured market access to Saudi Arabia to commercialise its 3D-printed craniofacial implants in partnership with medical technology firm Zimmer Biomet (NYSE:ZBH).
The expansion builds upon the original distribution agreement executed by the two companies on July 16, 2024, to supply biomimetic products across Europe, the Middle East, Africa, and the Asia-Pacific region.
The partnership previously achieved commercial traction when product sales commenced across Europe, Australia, and Hong Kong on July 29, 2025.
Under the current framework, the expansion utilises the existing distribution infrastructure and regional headquarters that Zimmer Biomet established in Saudi Arabia in 2018.
Following the announcement, the Osteopore share price was unchanged at $0.005.
The company stated that the transaction is expected to position the business to capture broader healthcare opportunities across the Gulf Cooperation Council region.
Osteopore continues to focus on growing its global market footprint through commercial partnerships that accelerate the adoption of bioresorbable tissue engineering technologies.
